Phenotype–Genotype Correlation in Children with Neurofibromatosis Type 1

Abstract

Neurofibromatosis type 1 (NF1) is a common autosomal dominant disorder with an incidence of ∼1 in 4,000 live births. Neurofibromin, the gene product, is ubiquitously expressed at high levels in the nervous system and functions as a tumor suppressor. Haploinsufficiency of neurofibromin through mutation leads to an increased risk of developing benign and malignant tumors in affected individuals. Although NF1 has complete penetrance, it displays considerable inter- and intrafamilial variability in phenotypic expression which poses disease prediction and management problems. Some NF1 genotype–phenotype correlations have been described. To evaluate the genetic component of variable expressivity in NF1, we examined the phenotypic correlations between affected relatives in 52 NF1 patients from 45 families.

Keywords

phenotype - neurofibromatosis - genetic - mutation

• References

• 1 Online Mendelian Inheritance in Man Database - Entry #162200. http://www.omim.org/entry/162200 . Accessed January 1, 2017
• 2 Anderson JL, Gutmann DH. Neurofibromatosis type 1. Handb Clin Neurol 2015; 132: 75-86
• 3 Hirbe AC, Gutmann DH. Neurofibromatosis type 1: a multidisciplinary approach to care. Lancet Neurol 2014; 13 (08) 834-843
• 4 Marchuk DA, Saulino AM, Tavakkol R. , et al. cDNA cloning of the type 1 neurofibromatosis gene: complete sequence of the NF1 gene product. Genomics 1991; 11 (04) 931-940
• 5 Upadhyaya M, Huson SM, Davies M. , et al. An absence of cutaneous neurofibromas associated with a 3-bp inframe deletion in exon 17 of the NF1 gene (c.2970-2972 delAAT): evidence of a clinically significant NF1 genotype-phenotype correlation. Am J Hum Genet 2007; 80 (01) 140-151
• 6 Abramowicz A, Gos M. Neurofibromin in neurofibromatosis type 1 - mutations in NF1gene as a cause of disease. Dev Period Med 2014; 18 (03) 297-306
• 7 Trovó-Marqui AB, Tajara EH. Neurofibromin: a general outlook. Clin Genet 2006; 70 (01) 1-13
• 8 Upadhyaya M. Neurofibromatosis type 1: diagnosis and recent advances. Expert Opin Med Diagn 2010; 4 (04) 307-322
• 9 Valero MC, Martín Y, Hernández-Imaz E. , et al. A highly sensitive genetic protocol to detect NF1 mutations. J Mol Diagn 2011; 13 (02) 113-122
• 10 Ben-Salem S, Al-Shamsi AM, Ali BR, Al-Gazali L. The mutational spectrum of the NF1 gene in neurofibromatosis type I patients from UAE. Childs Nerv Syst 2014; 30 (07) 1183-1189
• 11 The Human Gene Mutation Database. http:/www.hgmd.org . Accessed January 1, 2017
• 12 Pasmant E, Sabbagh A, Spurlock G. , et al; members of the NF France Network. NF1 microdeletions in neurofibromatosis type 1: from genotype to phenotype. Hum Mutat 2010; 31 (06) E1506-E1518
• 13 Alkindy A, Chuzhanova N, Kini U, Cooper DN, Upadhyaya M. Genotype-phenotype associations in neurofibromatosis type 1 (NF1): an increased risk of tumor complications in patients with NF1 splice-site mutations?. Hum Genomics 2012; 6: 12
• 14 Castle B, Baser ME, Huson SM, Cooper DN, Upadhyaya M. Evaluation of genotype-phenotype correlations in neurofibromatosis type 1. J Med Genet 2003; 40 (10) e109
• 15 Sabbagh A, Pasmant E, Laurendeau I. , et al; members of the NF France Network. Unravelling the genetic basis of variable clinical expression in neurofibromatosis 1. Hum Mol Genet 2009; 18 (15) 2768-2778
• 16 Stewart DR, Brems H, Gomes AG. , et al. Jaffe-Campanacci syndrome, revisited: detailed clinical and molecular analyses determine whether patients have neurofibromatosis type 1, coincidental manifestations, or a distinct disorder. Genet Med 2014; 16 (06) 448-459
• 17 Friedrich RE, Mautner VF, Scheuer HA. Loss of heterozygosity in tumor cells of a recurrent mandibular giant cell granuloma in neurofibromatosis type 1. Anticancer Res 2007; 27 (4A): 2079-2083